HSK21542
As of the edition of 20 October 2026, HSK21542 is a drug known only by a code name: in active development; acts on OPRK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Code name only
- Registered trials
- 16, 0 stopped early
- Disease areas
- Skin and connective tissue; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRK1 | Kappa-type opioid receptor | P41145 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 5 | 4 | 0 | 0 |
| Phase 2 | 5 | 3 | 1 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sichuan Haisco Pharmaceutical | Lead sponsor of trials | 2020 to now |
| Haisco Pharmaceutical | Lead sponsor of trials | 2020 to now |
| Xizang Haisco Pharmaceutical | Lead sponsor of trials | 2024 to now |